**IN8bio, Inc. Reports Financial Results and Operational Progress in Annual Filing**
IN8bio, Inc., a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, released its 10-K filing, detailing its financial performance and operational developments. The company reported a net loss of $19.4 million for the year ended December 31, 2025, compared to a net loss of $30.4 million for the previous year. Research and development expenses decreased to $10.2 million from $17.0 million in 2024, primarily due to reduced clinical trial costs for INB-200 and INB-400 programs, and lower personnel-related expenses. General and administrative expenses also decreased to $9.7 million from $12.6 million, driven by lower insurance premiums and professional service fees.
The company's strategic focus remains on its DeltEx platform, which leverages gamma-delta T cells for cancer and autoimmune disease treatments. Key operational developments include ongoing Phase 1 trials for INB-100, an allogeneic gamma-delta T cell therapy for high-risk leukemias, and INB-200, a drug-resistant immunotherapy for newly diagnosed glioblastoma (GBM). IN8bio presented updated data on INB-100 at the 2025 Transplantation & Cellular Therapy Meeting, showing 100% complete remission in acute myeloid leukemia (AML) patients with a median follow-up of 20.1 months. The company also presented longer-term follow-up data on INB-200 at the American Society of Clinical Oncology (ASCO) Annual Meeting.
A significant strategic decision was the suspension of further enrollment in the Phase 2 trial of INB-400, a company-sponsored clinical program evaluating autologous DeltEx DRI product candidate in newly diagnosed GBM, to conserve capital. However, the company continues to monitor enrolled patients and expects to provide further clinical updates in mid- and late-2026. IN8bio is also advancing INB-619, a CD19-targeted gamma-delta T cell engager (TCE) for potential applications in oncology and autoimmune diseases, with plans to present preliminary animal model data in 2026 and submit an IND in 2027.
The filing also addresses IN8bio's financial position, noting existing cash of $27.1 million as of December 31, 2025, is not anticipated to fund projected operating expenses and capital expenditure requirements after April 2027, raising substantial doubt about the company's ability to continue as a going concern. The company is actively pursuing additional funding through equity and debt financings, strategic collaborations, and licensing arrangements. In December 2025, IN8bio completed a private placement, generating net proceeds of $18.5 million. The company is also taking cash preservation measures to defer or reduce costs in the near term.
About IN8BIO, INC.
IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer and autoimmune diseases. Its proprietary DeltEx platform enables ex vivo expansion, genetic engineering, and scalable manufacturing of allogeneic, autologous, and iPSC-derived T cells. The company focuses on innovative immunotherapies, including T cell engagers, targeting solid and hematologic cancers to improve patient outcomes and achieve durable remissions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.